Evidence map›Paper›PMID 40895611›Full record

ArticleInfection and drug resistance2025

Comparative Genomic Analysis of Tigecycline Resistance Development in Clinical

Xiaoxia Li, Junnian Liu, Xinyu Zhang, Juan Li, Luhan Xuan, Sue Yuan, Jianglin Li, Yu Sun, Xuefei Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoxia Li *Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Junnian Liu *Department of Blood Transfusion, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Xinyu ZhangClinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Juan LiDepartment of Clinical Laboratory, Yunnan Fuwai Cardiovascular Disease Hospital, Kunming, Yunnan, People's Republic of China.
Luhan XuanClinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Sue YuanClinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Jianglin LiClinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Yu SunClinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Xuefei DuClinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.ORCID 0000-0001-8313-7464

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study investigated the mechanisms underlying the reduced tigecycline sensitivity of Methods: We conducted dynamic tracking of multidrug-resistant Results: Molecular typing and phylogenetic analysis confirmed that the tigecycline-resistant Conclusion: The use of tigecycline promotes the development of tigecycline resistance in

Indexed as

Acinetobacter baumanniicomparative genomicstigecycline

Identifiers

PMID40895611
PMCPMC12393085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.